GCP
ABUS icon

GSA Capital Partners’s Arbutus Biopharma ABUS Stock Holding History

GSA Capital Partners’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-36,923
Closed -$85K – 1443
2023
Q2 		$85K Sell
36,923
-1,237
-3% -$3.22K 0.01% 1391
2023
Q1 		$116K Sell
38,160
-79,031
-67% -$223K 0.01% 1337
2022
Q4 		$273K Buy
117,191
+22,391
+24% +$53.6K 0.03% 999
2022
Q3 		$181K Buy
94,800
+78,664
+488% +$185K 0.02% 1258
2022
Q2 		$44K Sell
16,136
-16,317
-50% -$41.8K 0.01% 1297
2022
Q1 		$97K Buy
+32,453
New +$99.3K 0.01% 1298
2021
Q2 		– Sell
-309,839
Closed -$1.03M – 1285
2021
Q1 		$1.03M Buy
309,839
+283,618
+1,082% +$1.09M 0.17% 125
2020
Q4 		$93K Buy
+26,221
New +$91.8K 0.02% 1103

Other funds holding ABUS

WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return